Description
DIVAA™isthefirstinvivosystemforthestudyofangiogenesisthatprovidesquantitativeandreproducIBLeresults.Duringthecourseoftheassay,implantgradesiliconecylindersclosedatoneend,calledangioreactors,arefilledwith20μlofTrevigen’sPathClear®basementmembraneextract(BME)premixedwithorwithoutangiogenic-modulatingfactors*.Theseangioreactorsarethenimplantedsubcutaneouslyinthedorsalflankofnudemice.Accompaniedwiththeonsetofangiogenesis,vascularendothelialcellsproceedtogrowintotheBMEandformvesselsintheangioreactor.Asearlyasninedayspost-implantation,thereareenoughcellstodetermineaneffectivedoseresponsetoangiogenicmodulatingfactors.Thesleekdesignoftheangioreactorprovidesastandardizedplatformforreproducibleandquantifiableinvivoangiogenesisassays.Comparedtotheplugassay,theangioreactorpreventsassayerrorsduetoabsorptionofthebasementmembraneextractbythemouse.Inaddition,theangioreactorusesonlyafractionofthematerialsconservingbothBMEandtestcompoundsused,anduptofourangioreactorsmaybeimplantedineachmouse,allowingforgreaterstatisticalpower.Trevigen’sDIVAAhasbeenusedinavarietyofinvestigations.
*ThePathClear®designationmeans:
- Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPXXIVChapter71sterilitytest.
- NegativebyPCRtestfor:mycoplasma,17bacterialandvirusstrainstypicallyincludedinmouseantibodyproduction(MAP)testing,plus13additionalmurineinfectiousagentsincludingLDEV,foratotalof31organismsandviruses.
| Catalog#3450-048-Kincludes: | ||
| CatalogNumber | Description | Qty |
| 3450-048-02 | DIVAABME | 1 |
| 3450-048-04 | DIVAAFGF-2PositiveControl | 1 |
| 3450-048-05 | DIVAACellSperse | 1 |
| 3450-048-B9 | DIVAAFGF-2(300ng)/VEGF(100ng) | 1 |
| 3450-048-01 | DIVAAAngioreactor | 1 |
| 3450-048-03 | DIVAAWashBuffer | 1 |
| 3450-048-06 | DIVAAFITC-Lectin200X | 1 |
| 3450-048-07 | 25XFITC-LectinDiluent | 1 |
| 3450-048-08 | HeparinSolution | 1 |
